GlassScriptPhysician profile
Paul H Miller
NPI 1073507224
$6,176.80
in general payments reported to CMS, 2019-2025
36 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $460 · 2021: $580 · 2022: $1,015 · 2023: $1,370 · 2024: $961 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,565.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $738.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $659.09 | 2021-2025 | |
| Amarin Pharma, INC. | $600.20 | 2019-2023 | |
| Lilly USA, LLC | $532.06 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $431.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $384.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.86 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $291.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $230.34 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $193.26 | 2019-2025 | Trintellix |
| Abbott Laboratories | $191.40 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.10 | 2023-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $173.74 | 2019-2025 | Veozah |
| Dexcom, INC. | $136.51 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $118.97 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.